H. Hampel, Coralie Williams, A. Etcheto
Jan 1, 2020
Citations
3
Influential Citations
39
Citations
Journal
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Abstract
The search for drugs to treat Alzheimer's disease (AD) has failed to yield effective therapies. Here we report the first genome‐wide search for biomarkers associated with therapeutic response in AD. Blarcamesine (ANAVEX2‐73), a selective sigma‐1 receptor (SIGMAR1) agonist, was studied in a 57‐week Phase 2a trial (NCT02244541). The study was extended for a further 208 weeks (NCT02756858) after meeting its primary safety endpoint.